Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Al 36904, USA.
Neoplasia. 2021 Sep;23(9):1002-1015. doi: 10.1016/j.neo.2021.06.010. Epub 2021 Aug 8.
Ovarian cancer (OC) is one of the most lethal type of cancer in women due to a lack of effective targeted therapies and high rates of treatment resistance and disease recurrence. Recently Poly (ADP-ribose) polymerase inhibitors (PARPi) have shown promise as chemotherapeutic agents; however, their efficacy is limited to a small fraction of patients with BRCA mutations. Here we show a novel function for the Hedgehog (Hh) transcription factor Glioma associated protein 1 (GLI1) in regulation of key Fanconi anemia (FA) gene, FANCD2 in OC cells. GLI1 inhibition in HR-proficient OC cells induces HR deficiency (BRCAness), replication stress and synergistic lethality when combined with PARP inhibition. Treatment of OC cells with combination of GLI1 and PARP inhibitors shows enhanced DNA damage, synergy in cytotoxicity, and strong in vivo anticancer responses.
卵巢癌 (OC) 是女性中最致命的癌症类型之一,原因是缺乏有效的靶向治疗方法以及治疗耐药性和疾病复发率高。最近,聚(ADP-核糖)聚合酶抑制剂 (PARPi) 作为化疗药物显示出前景;然而,它们的疗效仅限于一小部分 BRCA 突变的患者。在这里,我们展示了 Hedgehog (Hh) 转录因子 Glioma associated protein 1 (GLI1) 在调节关键的 Fanconi 贫血 (FA) 基因 FANCD2 在 OC 细胞中的新功能。在 HR 功能正常的 OC 细胞中抑制 GLI1 会诱导 HR 缺陷(BRCAness)、复制应激,并与 PARP 抑制联合使用时具有协同致死性。用 GLI1 和 PARP 抑制剂的组合治疗 OC 细胞会导致 DNA 损伤增加、细胞毒性协同作用以及体内抗癌反应增强。